← Leaderboards
Ayman K. Hamouda
Texas A&M University Health Science Ctr
$1,512,678
Attributed
$2,475,496
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $890.5K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,475,496 · 3
By mechanism
R01$1,444,227 · 1
R16$588,000 · 1
R15$443,269 · 1
Top collaborators
- Christie D Fowler2 shared
- Ganesh A Thakur2 shared
Most similar at Texas A&M University Health Science Ctr
Same institution · by research overlap
- Rahul Srinivasan$1,956,725
- Rajesh C Miranda$10,546,165
- Feng Tao$6,017,899
- Roger C Garcia$38,132
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsFuturePharmaceutical PreparationsBrainAffinityNicotinic ReceptorsIn VitroChemosensitizationDrug DevelopmentMutation AnalysisAnalogCharacteristicsPositive Allosteric ModulatorLeadProgramsBehavioralBindingLigandsPropertyIn VivoAgonistAwardMolecularBiomedical Research
Grant awards (8)
Selective Positive Allosteric Modulators of a4b2 Nicotinic Receptors$700,679
R01 · FY2025 · DA
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2025 · NS · contact PI
Selective Positive Allosteric Modulators of a4b2 Nicotinic Receptors$743,548
R01 · FY2024 · DA
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2024 · NS · contact PI
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2023 · NS · contact PI
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2022 · NS · contact PI
Neuronal nicotinic acetylcholine receptors (nAChRs)$326,006
R15 · FY2015 · NS · contact PI
Neuronal nicotinic acetylcholine receptors (nAChRs)$117,263
R15 · FY2015 · NS · contact PI